tirzepatide chronic kidney disease trial A Study of (LY3298176) in Participants With Overweight or Obesity and With or Without Type 2 Diabetes (TREASURE-CKD) SURPASS-4: Tirzepatide slows kidney disease
Pay in 4 interest-free payments of $6.37 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Live Spec
SURPASS 4: Tirzepatide slows kidney disease in adults with type 2 diabetes, CV risk Interplay of Chronic Kidney Disease and the Effects of Tirzepatide in Patients With Heart Failure, Preserved Ejection Fraction, and Obesity: The SUMMIT Trial JACC Long term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial Nature Medicine Randomized clinical trials evaluating kidney outcomes of sodium glucose Download Scientific Diagram Influence of Type 2 Diabetes on the Effects of Tirzepatide in Patients With Heart Failure and a Preserved Ejection Fraction With Obesity: A Prespecified Stratification Based Analysis JACC Not currently a kidney therapy. But this exploratory finding is worth watching closely. #ObesityMedicine #Tirzepatide #Type2Diabetes #KidneyHealth #ChronicKidneyDisease #GLP1 #GIP #CardiometabolicHealth #Nephrology #MetabolicHealth #CKD #T2DM
Store: www.allread.ai · Domain: www.allread.ai
























